191 related articles for article (PubMed ID: 34927311)
21. Silencing Signal Transducer and Activator of Transcription 3 (STAT3) and Use of Anti-Programmed Cell Death-Ligand 1 (PD-L1) Antibody Induces Immune Response and Anti-Tumor Activity.
Wang J; Huang F; Jiang C; Chi P
Med Sci Monit; 2020 Apr; 26():e915854. PubMed ID: 32343679
[TBL] [Abstract][Full Text] [Related]
22. Cooperativity of HOXA5 and STAT3 Is Critical for HDAC8 Inhibition-Mediated Transcriptional Activation of PD-L1 in Human Melanoma Cells.
Wang YF; Liu F; Sherwin S; Farrelly M; Yan XG; Croft A; Liu T; Jin L; Zhang XD; Jiang CC
J Invest Dermatol; 2018 Apr; 138(4):922-932. PubMed ID: 29174371
[TBL] [Abstract][Full Text] [Related]
23. Overexpressed ITGA2 promotes malignant tumor aggression by up-regulating PD-L1 expression through the activation of the STAT3 signaling pathway.
Ren D; Zhao J; Sun Y; Li D; Meng Z; Wang B; Fan P; Liu Z; Jin X; Wu H
J Exp Clin Cancer Res; 2019 Dec; 38(1):485. PubMed ID: 31818309
[TBL] [Abstract][Full Text] [Related]
24. NUCB2 inhibition antagonizes osteosarcoma progression and promotes anti-tumor immunity through inactivating NUCKS1/CXCL8 axis.
Ji R; Wang Y; Pan D; Han J; Wang Y; Zheng S; Zhao W; Li X; Han C; Zhang L
Cancer Lett; 2024 Jun; 591():216893. PubMed ID: 38636892
[TBL] [Abstract][Full Text] [Related]
25. Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells.
Ishibashi M; Yamamoto J; Ito T; Handa H; Sunakawa-Kii M; Inokuchi K; Morita R; Tamura H
Mol Cancer Ther; 2021 Jul; 20(7):1283-1294. PubMed ID: 33879556
[TBL] [Abstract][Full Text] [Related]
26. MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression.
Lin J; Xu A; Jin J; Zhang M; Lou J; Qian C; Zhu J; Wang Y; Yang Z; Li X; Yu W; Liu B; Tao H
Oncoimmunology; 2022; 11(1):2024941. PubMed ID: 35036076
[TBL] [Abstract][Full Text] [Related]
27. The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity.
Ostrand-Rosenberg S; Horn LA; Haile ST
J Immunol; 2014 Oct; 193(8):3835-41. PubMed ID: 25281753
[TBL] [Abstract][Full Text] [Related]
28. KLF12 transcriptionally regulates PD-L1 expression in non-small cell lung cancer.
Pan X; Zhang W; Wang L; Guo H; Zheng M; Wu H; Weng Q; He Q; Ding L; Yang B
Mol Oncol; 2023 Dec; 17(12):2659-2674. PubMed ID: 37606530
[TBL] [Abstract][Full Text] [Related]
29. PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer.
Diskin B; Adam S; Cassini MF; Sanchez G; Liria M; Aykut B; Buttar C; Li E; Sundberg B; Salas RD; Chen R; Wang J; Kim M; Farooq MS; Nguy S; Fedele C; Tang KH; Chen T; Wang W; Hundeyin M; Rossi JAK; Kurz E; Haq MIU; Karlen J; Kruger E; Sekendiz Z; Wu D; Shadaloey SAA; Baptiste G; Werba G; Selvaraj S; Loomis C; Wong KK; Leinwand J; Miller G
Nat Immunol; 2020 Apr; 21(4):442-454. PubMed ID: 32152508
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling.
Roshani Asl E; Rasmi Y; Baradaran B
J Cell Physiol; 2021 Oct; 236(10):7071-7087. PubMed ID: 33821473
[TBL] [Abstract][Full Text] [Related]
31. Curcumol inhibits the expression of programmed cell death-ligand 1 through crosstalk between hypoxia-inducible factor-1α and STAT3 (T705) signaling pathways in hepatic cancer.
Zuo HX; Jin Y; Wang Z; Li MY; Zhang ZH; Wang JY; Xing Y; Ri MH; Jin CH; Xu GH; Piao LX; Ma J; Jin X
J Ethnopharmacol; 2020 Jul; 257():112835. PubMed ID: 32278762
[TBL] [Abstract][Full Text] [Related]
32. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
[TBL] [Abstract][Full Text] [Related]
33. High linear energy transfer carbon-ion irradiation upregulates PD-L1 expression more significantly than X-rays in human osteosarcoma U2OS cells.
Permata TBM; Sato H; Gu W; Kakoti S; Uchihara Y; Yoshimatsu Y; Sato I; Kato R; Yamauchi M; Suzuki K; Oike T; Tsushima Y; Gondhowiardjo S; Ohno T; Yasuhara T; Shibata A
J Radiat Res; 2021 Sep; 62(5):773-781. PubMed ID: 34196706
[TBL] [Abstract][Full Text] [Related]
34. Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity.
Tao Z; Ruan H; Sun L; Kuang D; Song Y; Wang Q; Wang T; Hao Y; Chen K
Cancer Immunol Res; 2019 Jul; 7(7):1135-1147. PubMed ID: 31113805
[TBL] [Abstract][Full Text] [Related]
35. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma.
Koirala P; Roth ME; Gill J; Piperdi S; Chinai JM; Geller DS; Hoang BH; Park A; Fremed MA; Zang X; Gorlick R
Sci Rep; 2016 Jul; 6():30093. PubMed ID: 27456063
[TBL] [Abstract][Full Text] [Related]
36. Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-κB/STAT3 and NF-κB/CSN5 signaling pathways.
Ruan Z; Liang M; Shang L; Lai M; Deng X; Su X
Pancreatology; 2021 Apr; 21(3):630-641. PubMed ID: 33707115
[TBL] [Abstract][Full Text] [Related]
37. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma.
Kearl TJ; Jing W; Gershan JA; Johnson BD
J Immunol; 2013 Jun; 190(11):5620-8. PubMed ID: 23616570
[TBL] [Abstract][Full Text] [Related]
38. A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation.
Haile ST; Horn LA; Ostrand-Rosenberg S
Cancer Immunol Res; 2014 Jul; 2(7):610-5. PubMed ID: 24819296
[TBL] [Abstract][Full Text] [Related]
39. Demethylase JMJD2D induces PD-L1 expression to promote colorectal cancer immune escape by enhancing IFNGR1-STAT3-IRF1 signaling.
Chen Q; Zhuang S; Hong Y; Yang L; Guo P; Mo P; Peng K; Li W; Xiao N; Yu C
Oncogene; 2022 Mar; 41(10):1421-1433. PubMed ID: 35027670
[TBL] [Abstract][Full Text] [Related]
40. Radiotherapy Upregulates Programmed Death Ligand-1 through the Pathways Downstream of Epidermal Growth Factor Receptor in Glioma.
Song X; Shao Y; Jiang T; Ding Y; Xu B; Zheng X; Wang Q; Chen X; Gu W; Wu C; Jiang J
EBioMedicine; 2018 Feb; 28():105-113. PubMed ID: 29396299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]